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Abstract 
 
Background: Increased occurrence of chronic syndromes has prompted researchers to investigate and develop drugs 
and methods for controlling chronic syndromes with a view to improve human health and reduce early aging.  
Material and methods: Human trials: After the allotted multivitamin pills or placebo pills had been taken for a 
stipulated period of about 2 months, the volunteers filled out feedback forms on curative effects of the pills in line with 
the health examination reports. The effects of the multivitamin on various symptoms or diseases and dysfunctions of 
the chronic metabolic syndromes were noted and evaluated based on the information provided in forms.  
Animal experiments: Mouse aging model induced by D-galactose were administered the multivitamin by oral gavage 
every morning. At the end of the sixth week, activity or content of the components associated with ageing and 
anti-aging in the brain and liver of the aging mice were determined to investigate the mechanisms of the new 
multivitamin on chronic metabolic syndromes and aging.  
Results: We found that multivitamin can eliminate or attenuate 38 types of symptoms or dysfunctions of the 
investigated metabolic syndromes; and that it has both preventive and curative/adjunctive therapeutic effects on the 
metabolic syndromes. The effects of this multivitamin on components associated with aging and anti-aging were 
significantly decreased - malondialdehyde content and monoamine oxidase activity but significantly increased activity 
of superoxide dismutase and glutathione peroxidase. This multivitamin has significant anti-aging effects.  
Conclusion: Supplementing with this multivitamin can prevent and provide treatment/ adjunctive therapy for these 
chronic metabolic syndromes and delay the aging process.  
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List of Abbreviations: BW, body weight; Cu/Zn-SOD, cuprum/zinc-superoxide dismutase; MAO, 
monoamine oxidase; MDA, malondialdehyde; Mn-SOD, manganese-superoxide dismutase; 
T-SOD, total superoxide dismutase; TP, total protein. 
 
Introduction  
 
Although remarkable progress has been made in research on the aetiology and pathogenesis of human chronic 
metabolic syndromes and chronic diseases, especially their genetic basis (Arner, et al. 2011; Hotamisligil, 2006; Mani, 
et al. 2007; Turek et al., 2005), their occurrence keep increasing. The prevention and treatment of some chronic 
metabolic syndromes have for long become global issues in medicine (Vijg, et al. 2008). Conducting research and 
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developing drugs for prevention and treatment of chronic metabolic syndromes and decreased aging process have great 
scientific impact and wide application value for improving the health of the people and retards the aging process (Bard, 
2006; Chen, et al. 2008; Rader, et al. 2008).  
The life processes of organisms essentially consist of a series of enzymatic reactions. If an enzymatic biochemical 
reaction is interrupted, the physiological function is affected, which may in turn cause diverse chronic disease, 
especially chronic metabolic syndromes and accelerate aging (Khor, et al. 2011; Bensinger, et al. 2008; 
Chocano-Bedoya et al., 2011). 
When aging, malondialdehyde (MDA) content and monoamine oxidase (MAO) activity increase, whereas 
superoxide dismutase (SOD) activity and glutathione peroxidase (GSH-Px) activity decreases. Studies have shown that 
MDA is an important component that accelerates aging of the body; such that increase in the MAO activity increases 
the breakdown of monoamine neurotransmitters and affect body health; the GSH-Px activity and SOD activity increase 
can accelerate the removal of free radicals and peroxides and delay aging. Therefore, MDA content, MAO activity, 
GSH-Px activity and SOD activity are important parameters for assessing the severity of body aging and health (Chen, 
et al. 2000; Li, et al. 2007; Pan, et al. 2012). 
Modern studies have confirmed that vitamins B-1, B-2, B-6 and PP are key components that form many coenzymes 
(thiamine pyrophosphate, flavin adenine dinucleotide, flavin mononucleotide, pyridoxal phosphate, nicotinamide 
adenine dinucleotide, nicotinamide adenine dinucleotide phosphate) (Wang, et al. 2002). Those coenzymes participate 
in more than 300 enzymatic reactions related to the metabolism of matter–energy and protein. For example, the 
coenzymes that make up vitamin PP participate in more than 200 enzymatic reactions related to matter–energy 
metabolism (Huang, 2003), and those that make up vitamin B-6 participate in approximately 100 enzymatic reactions 
related to the metabolism of proteins and fat (Wu, 2005). Those coenzymes play a key role in the transfer of hydrogen 
ions and electrons, decarboxylation, transamination and racemisation in those enzymatic reactions (Wang, et al. 2002). 
Vitamins B-1, B-2, B-6 and PP can improve matter-energy metabolism and protein metabolism and to prevent the 
formation and the accumulation of the components associated with chronic metabolic syndromes and aging in 
organisms and strengthen the body’s health by means of their synergistic effects (Wang, et al. 2002; Huang, 2003; Wu, 
2005). So we believed that chronic metabolic syndromes and aging process can be controlled through supplementing 
with vitamins B-1, B-2, B-6, PP and antioxidant vitamins.   
In order to verify our conjecture, we performed human trials, animal experiments, and biochemical analysis of the 
components (MDA, MAO, GSH-Px and SOD) associated with aging and anti-aging to investigate the effects and 
mechanisms of a new multivitamin on chronic metabolic syndromes and aging. We found this multivitamin can 
eliminate or attenuate many symptoms ore dysfunctions of the investigated chronic metabolic syndromes and delay the 
aging process.  
Material and Methods 
Design of multivitamin 
 
When we developed this multivitamin, we took into consideration the causes and Mechanism of chronic metabolic 
syndromes and age-related diseases (see Additional file 1). We determined the basal dosage of various vitamins 
according to the recommended nutrient intake for adult. Our focus was on creating a new multivitamin with suitable 
proportions of vitamins PP, B-1, B-2 and B-6 and of antioxidant vitamins. This process also involved factoring in the 
synergistic effects of these components. Specifically, we increased the amount of vitamin PP and B-6 according to their 
importance in controlling chronic metabolic syndromes and decreased the number of fat-soluble vitamins (vitamins A 
and E), which have been reported as producing side effects (Bjelakovic, et al. 2007). A multivitamin pill contains 50 mg 
of vitamin PP; 50 mg of vitamin C; 12.5 mg of vitamin E; 5 mg each of vitamins B-1, B-2 and B-6; 0.8 mg of vitamin 
A; and 121.7 mg of medical starch. This multivitamin differs from standard commercial multivitamin pills, possesses 
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good curative effects on chronic metabolic syndromes and produces no chronic toxicity (Tao et al.,2012). 
 
Human trials 
 
The study was performed as a single blind randomized controlled trial in the People’s Hospital of Hunan Province 
and the Hospital of Changsha University of Science and Technology. A group of individuals (volunteers, n=76) 
identified as suffering from various chronic metabolic syndromes or a sub-health condition were selected to participate 
in human trials. Volunteers were excluded from the study if they had an allergy for nicotinic acid. They were randomly 
assigned to either the experimental group (n = 56) or the control group (n = 20). The volunteers in the experimental 
group received 2 bottles of the multivitamin pills (1 bottle = 100 pills) and the volunteers in the control group received 
2 bottles of placebo pills (a pill of the placebo contains 250 mg of medical starch). All the volunteers received feedback 
forms (see table S1 of additional file 2) and instructions for using the multivitamin or placebo (usage methods and 
dosage of the multivitamin and the placebo：Oral administration after meals, 1–10 days, 3 times a day, 2 pills each time; 
11–30 days, 2 times a day, 2 pills each time; 31–60 days, 2 times a day, 1–2 pills each time. After 60 days, the 
multivitamin was taken according to the needs of the body). We did not ask the volunteers to undergo any other 
treatments, except for those with severe hypertension, coronary heart disease, diabetes and infections, nor did we give 
them any advice concerning diet, lifestyle and exercise. After the allotted multivitamin pills or placebo pills had been 
taken for a time period of 2 months, the volunteers filled out feedback forms to show their curative effects according to 
the table S1 of Additional file 2 and Additional file 3. The feedback forms and health examination reports were either 
returned by the volunteers or collected by us. The effects of the multivitamin on various symptoms or diseases and 
dysfunctions of the chronic metabolic syndromes were counted and evaluated based on health examination reports and 
the information provided on the feedback forms regarding curative effects. 
The study was approved by the Medical Research Ethics Committee of the Changsha University of Science and 
Technology, China, and written consents were obtained from all volunteers. 
 
Animal experiments 
 
 To explore the mechanisms of the investigated multivitamin in aging process, we also conducted tests on the mouse 
aging model induced by D-galactose. The aging animal model was integrated with animal model design based on the 
principle of metabolic disturbance in the aging process. That is, each organ exhibits different degrees of senile 
symptoms, and, accordingly, aged-related biochemical parameters in the body change by aging. This aging model is the 
ideal experimental tool for studying metabolic diseases, age-related diseases and anti-aging effects and has been widely 
used to study the anti-aging action of drugs and functional foods (Lu, et al. 2007; Song, et al. 1999; Zhang, 2007). 
Following a 7-day acclimation period, 50 mice were randomly assigned to different groups 1 of 5 (3 dose 
experimental groups, 1 aging model group, and 1 control group) of 10 mice (5 males; 5 females) each. They were 
allowed free access to food and water. The mice in the high-medium and low-dose experimental groups and in the 
aging model group were subcutaneously injected with D-galactose at a dose of 150 mg/kg once daily for 6 weeks, 
whereas those in the control group were treated with the same volume of physiological saline (0.5 mL). At 
approximately the same time, the aging mice in the high-medium and low-dose experimental groups were administered 
multivitamin at doses of 42.32, 21.66, and 10.83 mg/kg BW/day by oral gavage, respectively, every morning, with the 
mice in the aging model group and the control group receiving the same volume of distilled water (0.4 mL/10 g 
BW/day). Weekly adjustments were made for BW changes. Following treatment, clinical observations were made. The 
general condition of all animals was recorded every day. At the initiation of the experiments and at the end of every 
other week, BWs were measured. Throughout the experiments, food consumption was recorded every day, and the 
average food consumption per animal was calculated at weekly intervals. At the end of the sixth week, the animals were 
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euthanized to undergo a gross pathological examination. The brain and liver were then removed from each cadaver for 
biochemical analysis. 
The brain and the liver were homogenised by a method traditionally used in the literature, and the supernatant liquid 
of the homogenate was removed for biochemical analysis. The MDA content, total superoxide dismutase (T-SOD) 
activity, cuprum/zinc-superoxide dismutase (Cu/Zn-SOD) activity, GSH-Px activity, MAO activity, and total protein 
(TP) content were determined with the appropriate biochemical analysis kits (Nanjing Jiancheng Bioengineering 
Institute, Nanjing, China) and the UV754N ultraviolet spectrophotometer (Shanghai Exact Scientific Instrument, 
Shanghai, China) in accordance with the respective kit instructions. Thereafter, the effects and mechanisms of this 
multivitamin in delaying aging were determined based on its impact on the components associated with aging and 
anti-aging.  
 
Statistical analysis 
 
 Data are presented as mean ± SEM. The significance of the difference between the control group and the treated 
groups for total BWs and food consumption values for mice, content and activity of the components associated with 
aging and anti-aging in brain and liver was analyzed with Statistical Product and Service Solutions software, version 
11.5 (analysis of variance: Student Newman-Keuls). Statistical significance was established at p < 0.05. 
 
Results 
Human trial results 
 
At the end of human trials, we collected the feedback forms on the curative effects (see Table S2–S44 of Additional 
file 2) and the health examination reports (see Table S1-S13 of Additional file 4) from the experimental group and the 
control group. Statistical analyses suggest that the multivitamin can eliminate and/or attenuate 38 types of symptoms or 
chronic diseases and dysfunctions of the investigated chronic metabolic syndromes (see table 1) and has preventive and 
curative / adjunctive therapeutic effects on the chronic metabolic syndromes. Chronic metabolic syndromes of the 
volunteers in the control group did not show any improvement and they looked older (see Fig. S1 of Additional file 5).  
 
Table 1: Effects of the multivitamin on various symptoms and dysfunction of chronic metabolic syndromes (N=56). 
Effects of the multivitamin on symptoms or dysfunction of 
chronic metabolic syndromes 
Evaluation 
A. 
Cure 
B. Substantial 
effect 
C. Some 
effect 
D. No 
effect 
Improved resistance; prevented cold or rheums  17 12  
provided adjunctive therapy for colds; reduced recovery 
time for colds 
  
16 
 
13 
 
Prevented and treated chronic enteritis 1 5 13  
Prevented and treated chronic rhinitis 1 7 16  
Prevented and treated chronic faucitis 1 5 9  
Prevented and treated itchy skin 3 6 4  
Prevented and provided treatment/ adjunctive therapy for 
intractable skin diseases 
 
2 
 
2 
  
Prevented and treated anal itching 4 1 1 1 
Prevented and treated dandruff and itchy scalp 4 6 7 1 
Prevented and treated dizziness 3 3 8  
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Enhanced memory  7 1  
Enhanced male sexual function and delayed ejaculation  5 3  
Eliminated pigment spots/ age pigments 2 5 9  
Prevented and treated chest discomfort or chest pain 
induced by exercise or fast walking 
 
3 
 
3 
 
1 
 
Prevented and provided treatment/ adjunctive therapy for 
heart disease 
  
4 
 
5 
 
Prevented and provided treatment/ adjunctive therapy for 
hypertension or stabilized blood pressure  
 
 
1 
 
 
6 
 
 
4 
 
 
1 
Provided rehabilitation of lumbar intervertebral disc 
protrusion sequelae 
 
3 
 
3 
 
4 
 
Prevented and treated physical weakness and heavy feet or 
inability to walk 
 
2 
 
3 
 
4 
 
Prevented and treated gingival bleeding 5 8 8  
Prevented and treated bad breath (halitosis) 4 3 3  
Prevented and treated odontopathy  
and loose teeth 
 
2 
 
3 
 
2 
 
Prevented and treated oral cavity ulcers 3 4 5  
Prevented and provided treatment/adjunctive therapy for 
intractable tinea pedis 
 
1 
 
1 
 
3 
 
1 
Prevented and provided treatment/ adjunctive therapy for 
leuconychia and nail deformities 
  
3 
 
2 
 
1 
Prevented and provided treatment/ adjunctive therapy for 
intractable facial acne 
  
3 
 
1 
 
Prevented and treated gynecopathy 1  1  
Eliminated skin nodules 1 2 1  
Eliminated dewlaps 1  2  
Increased skin elasticity, reduced skin wrinkles (anti-aging 
effects) 
  
15 
 
9 
 
Anti-fatigue  12 8  
Darkened hair and body hair    4   
Prevented and treated hemorrhoids 2    
Prevented and treated chronic tympanitis 1    
Prevented and treated hyperacidity  1 1   
Prevented and treated trigeminal neuralgia  1   
Treated sequelae of lumbar injury   1   
Prevented and treated melancholia  1   
Cerebral hemorrhage sequelae  1   
 
The results of the animal experiments 
 
The results of the animal experiments indicated that the mice in the aging model group exhibited obvious senility 
symptoms, such as reduced activity; sparse, dull yellow fur; irritable temperament, and thin dejecta. The appearance, 
behaviour, urine and fur of mice in the three dose groups were similar to those in the control group. A summary of total 
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BW (Table S1) and food consumption values (Table S2) is presented in Additional file 6. Contrastive analysis showed 
no statistically significant changes in food consumption and BW values between the three dose groups and the control 
group (p > 0.05). However, food consumption and BW values of the aging group were significantly lower than those of 
the dose groups and those of the control group (p < 0.05). 
The MDA content and MAO activity in the brain and liver of the mice in each group were determined with MDA and 
MAO kits, respectively. Results are shown in Table 2. 
The GSH-Px activity in the brain and liver of the mice in each group were determined with a GSH-Px kit. Results are 
presented in Table 3. 
The T-SOD and CuZn-SOD activity in the brain and liver of the mice in each group were determined with an SOD 
typing kit. The activity of Mn-SOD equals the activity of T-SOD minus the activity of CuZn-SOD. Results are shown 
in Table 4 and 5. Contrastive analysis showed that the MDA content and MAO activity of the brain and the liver of the 
mice in the aging model group were significantly higher than those of the control group (p < 0.01), and the GSH-Px 
activity, T-SOD activity, CuZn-SOD activity, and Mn-SOD activity of the mice in the aging model group was 
significantly lower than that of the control group (p < 0.01). This finding shows that the injection of D-galactose into 
mice induced changes related to aging and confirmed that the construction of the mouse aging model was successful. 
Contrastive analysis showed no statistically significant changes in the MDA content, MAO activity, GSH-Px activity, 
T-SOD activity, CuZn-SOD activity, and Mn-SOD activity among the three dose groups, nor between the dose groups 
and the control group (p > 0.05); however, they significantly differed (p < 0.05) or very significantly differed from 
those in the aging model group (p < 0.01). This finding demonstrates the remarkable anti-aging effect of this 
multivitamin.  
 
Table 2:  Effects of the multivitamin on MDA content and MAO activity of brain and liver of mice in each group 
(n=10) 
Group 
MDA (nmol/mgprot) MAO (U/mgprot) 
Brain Liver Brain Liver 
Low dose 1.36±0.18
 †3, ‡2, §3 
1.34±0.14
 †3, ‡2, §3 
9.16±1.37
†3,‡1, §3 
2.17±0.22
†3,‡2, §3 
Medium dose 1.38±0.21
 †3, ‡2, §3
 1.36±0.16
 †3, ‡2, §3
 9.10±1.21
†3,‡1, §3
 2.06±0.17
†3,‡2, §3
 
High dose 1.55±0.21
†3, ‡1, §3
 1.45
 
±0.19
 †3, ‡2, §3
 9.00±1.10
†3,‡1, §3
 1.98±0.19
†3,‡2, §3
 
Aged model 1.77±0.3
§2 
1.82±0.18
§2 
10.78±2.12
§2 
2.78±0.13
§2 
Control 1.30±0.15
 
1.18±0.15
 
8.51±1.74
 
1.88±0.16
 
†  
denotes comparison among the three dose groups; 
†1：p < 0.05；†2：p <0.01；†3：p > 0.05. 
‡ 
denotes comparison between dose groups and aging model group, 
‡1：p < 0.05；‡2：p <0.01；‡3：p > 0.05. 
§ 
denotes comparison between dose groups, aging model groups and control group, 
§1：p < 0.05；§2：p <0.01；§3：p > 
0.05. 
Table 3: Effects of the multivitamin on GSH-Px activity of brain and liver of aging mice (n=10 mice; Unit = U/mgprot) 
Group Brain  Liver 
Low dose 162.81±29.21
 †3, ‡2, §3 
436.16±40.47 
†3, ‡1, §3 
Medium dose 169.5127.66
 †3, ‡2, §3
 441.17±37.43
 †3, ‡1, §3 
High dose 171.61±26.29
 †3,‡2, §3
 437.76±39.05
 †3, ‡1, §3
 
Aged model 106.78±7.92
§2
 368.30±57.85
§2
 
Control 187.88±19.88
 
447.50±60.19
 
† 
denotes comparison among the three dose groups;  
†1：p < 0.05；†2：p <0.01；†3：p > 0.05. 
‡ 
denotes comparison between dose groups and aging model group;  
‡1：p < 0.05；‡2：p <0.01；‡3：p > 0.05. 
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§ 
denotes comparison between dose groups, aging model group and control group;  
§1：p < 0.05；§2：p <0.01；§3：p > 
0.05. 
Table 4: Effects of the multivitamin on T-SOD activity, CuZn-SOD activity and Mn-SOD activity of brain of aging 
mice (n=10 mice; Unit =U/mgprot) 
Group  T-SOD             CuZn-SOD             Mn-SOD 
Low dose 207.18±31.29
 †3, ‡2, §3
 159.54±30.03 
†3, ‡2, §3
 47.64±9.78
†3, ‡2, §3
 
Medium dose 209.16±30.21
†3, ‡2, §3
 160.34±29.21
†3, ‡2, §3
 48.82±10.27
†3, ‡2, §3
 
High dose 208.68±31.57
†3, ‡2, §3
 161.65±28.92
†3, ‡2, §3
 49.77±11.07
†3, ‡2, §3
 
Aged model 156.65±14.92 
§2
 121.73±15.87 
§2
 34.92±10.44
 §2
 
Control 217.37±28.17  161.87±16.97  53.50±12.62  
† 
denotes comparison among the three dose groups;  
†1：p < 0.05；†2：p <0.01；†3：p > 0.05. 
‡ 
denotes comparison between dose groups and aging model group;  
‡1：p < 0.05；‡2：p <0.01；‡3：p > 0.05. 
§ 
denotes comparison between dose groups, aging model groups and control group;  
§1：p < 0.05；§2：p <0.01；§3：p > 
0.05. 
 
 Table 5: Effects of the multivitamin on T-SOD activity, CuZn-SOD activity and Mn-SOD activity of liver of aging 
mice (n=10 mice; Unit = U/mgprot). 
Group  T-SOD             CuZn-SOD           Mn-SOD 
Low dose 117.80±8.62 
†3, ‡2, §3
 102.60±4.80
 †3, ‡2, §3
 15.20±7.96
 †3, ‡2, §3
 
Medium dose 119.67±9.03
†3,‡2, §3
 104.63±5.12
†3,‡2, §3
 16.04±9.78
†3,‡2, §3
 
High dose 120.13±8.83
†3,‡2, §3
 103.98±4.16
†3, ‡2, §3
 17.70±10.08
†3,‡2, §3
 
Aged model 98.93±3.93 
§2
 87.36±6.86
 §2
 11.57±6.57 
§2
 
Control 123.72±13.67 104.56±8.73  19.16±10.62  
† 
denotes comparison among the three dose groups;  
†1：p < 0.05；†2：p <0.01；†3：p > 0.05. 
‡ 
denotes comparison between dose groups and aging model group;  
‡1：p < 0.05；‡2：p <0.01；‡3：p > 0.05. 
§ 
denotes comparison between dose groups, aging model groups and control group;  
§1：p < 0.05；§2：p <0.01；§3：p > 
0.05. 
 
Discussion 
 
We found that the symptoms and dysfunctions of these chronic metabolic syndromes occurred mainly in 
metabolically active tissues and organs (e.g., tissues and organs of the cardiovascular system; the digestive system; the 
skin; teeth and so on). These parts of the body need more energy and more protein so as to maintain normal function 
and structure. In addition, we found that this multivitamin had poor curative effects or were inefficacious in a few 
symptoms or chronic diseases of the chronic metabolic syndromes. Upon further investigation, we determined that the 
main reasons for its poor curative effects or inefficacy were inadequate dosage, shortened duration of multivitamin use 
or the presence of a secondary disease, because chronic metabolic syndromes is the result of cumulative damage over a 
period of time caused by long-term subclinical deficiencies in some important nutrients. Therefore, sufficient dose (4–6 
pills) and sufficient time are required to achieve a satisfactory therapeutic effect, and that a small dose of the 
investigated multivitamin (1–3 pills) has preventive effects for these chronic metabolic syndromes, and a high dose 
(4–6 pills) has curative/ adjunctive therapeutic effects for these chronic metabolic syndromes. 
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Mechanism of the multivitamin on chronic metabolic syndromes and aging 
 
The main reasons of preference for this multivitamin is that it is better than other multivitamins we took into 
consideration in the causes and Mechanism of chronic metabolic diseases and aging. Our focus was on creating a new 
multivitamin with suitable proportions of vitamins PP, B-1, B-2 and B-6 and of antioxidant vitamins. This process also 
involved factoring in the synergistic effects of these components. Specifically, we increased the amount of vitamin PP 
and B-6 according to their importance in controlling chronic metabolic syndromes and decreased the number of 
fat-soluble vitamins (vitamins A and E). Therefore, this multivitamin can prevent and provide treatment/ adjunctive 
therapy for many chronic metabolic diseases and significantly delay aging process. 
Why was the multivitamin able to eliminate and attenuate 38 types of symptoms or chronic diseases and 
dysfunctions of the chronic metabolic syndromes and delay significantly aging? Supplementing with these vitamins can 
increase the number of coenzymes. An increase in the number of coenzymes may increase the number of active 
enzymes. An increase in the number of active enzymes may make hundreds of interrelated enzymatic reactions occur 
more smoothly (Pauling, 1989), accelerate the oxidative decomposition of lipids and saccharides (such as D-galactose) 
into carbon dioxide and water in the body, prevent the production and accumulation of the components (for example 
galactitol, MDA, other peroxides and mesostates and so on) associated with metabolic syndromes and aging, and 
provide a large amount of energy. Studies have shown that improvements in the metabolism of matter–energy and 
protein are propitious to the synthesis of enzyme proteins (such as GSH-Px, CuZn-SOD, and Mn-SOD )( Li, et al. 2007; 
Pan, et al.2012; Li, et al.2013), structural proteins and other functional materials in the body and help to maintain the 
normal structure and function of histiocytes and DNA (Ribeiro, et al. 2007), especially the structure and function of 
histiocytes that are metabolically active, to prevent the occurrence of metabolic syndromes, especially chronic 
inflammation (Yang, et al. 2009). These improvements can enhance the regulatory functions of histiocytes on 
expression of enzymes associated with aging and anti-aging: significantly repressing the expression of the MAO and 
significantly promoting the expression of anti-oxidases. Studies have shown that repressing the expression of the MAO 
decelerate the breakdown of monoamine neurotransmitters and improve body’s health (Lindley, et al. 2005; Benedetti, 
et al. 1989; Chen, et al. 2000); that promoting the expression of anti-oxidase (GSH-Px, CuZn-SOD, and Mn-SOD) 
accelerate the removal of free radicals and peroxides (Li, et al. 2007; Pan, et al.2012; Li, et al.2013). Those active 
substances (GSH-Px, CuZn-SOD, and Mn-SOD) enhance the anti-aging effects. Studies have shown that improvements 
in the metabolism of matter–energy and protein are propitious to the ubiquitin proteasome pathway, which is dependent 
on adenosine triphosphate to accelerate the breakdown of lipofuscin and elimination of age pigments (Shang et al. 2011; 
Chondrogianni, et al. 2014; Löw, 2011).  
In addition to improving substance–energy metabolism, vitamin PP plays a role in expanding blood vessels (Huang, 
2003) and improving micro-circulation in the body (we found that microcirculation disturbance may be one of the 
leading causes of chronic disease in organic tissues), promoting the delivery of nutrients into the microcirculation 
system, accelerating the effusion of metabolic waste and harmful substances in the microcirculation system, enhancing 
the abilities of histiocytes to resist various harmful factors and preventing the occurrence of chronic diseases (Huang, 
2003; Wu, 2005). Furthermore, the synergistic effects of vitamins PP and B-1 can enhance the stability and regulatory 
function of the nervous system and the circulatory system, as well as prevent various stress factors from causing arterial 
vasospasm through neurological reflex and from inducing high blood pressure, thereby effectively controlling 
cardiovascular disease (Tao, et al. 2013). In conclusion, the optimal metabolism of materials, energy and proteins and 
microcirculation are the key to preventing chronic metabolic syndromes and to maintaining good health.  
By means of their antioxidant effects, vitamins C, E and A in the investigated multivitamin can eliminate peroxides 
and free radicals and their detrimental effects in the body and, in so doing, promote anti-aging (Cosgrove, et al. 2007).  
The main mechanism by which the multivitamin eliminates and attenuate symptoms or chronic diseases and 
dysfunctions of the chronic metabolic syndromes and delay aging is as follows: Several vitamins in combination 
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improve the metabolism of materials, energy, and proteins, as well as prevent the formation and accumulation of the 
components associated with chronic metabolic syndromes and aging, increase the level of antioxidases to eliminate 
peroxides, free radicals and their harmful effects. Their synergistic effects restore and maintain good health and delay 
aging. This study provides a theoretical basis and a scientific method for preventing and treating chronic metabolic 
syndromes, for delaying aging.  
 
Conclusion 
 
The multivitamin can eliminate or attenuate 38 types of symptoms or chronic diseases and dysfunctions of the 
investigated chronic metabolic syndromes and has significant effects for anti-aging. Supplementing with this 
multivitamin can prevent and provide treatment/ adjunctive therapy for these chronic metabolic syndromes and delay 
aging process.  
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